Literature DB >> 10096037

Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.

J Romero1, F Berrendero, L García-Gil, J A Ramos, J J Fernández-Ruiz.   

Abstract

The inhibition of motor behavior in rodents caused by the exposure to plant or synthetic cannabinoids has been reported to develop tolerance after repeated exposure. This tolerance seems to have a pharmacodynamic basis, since downregulation of cannabinoid receptors in motor areas, basal ganglia and cerebellum, has been demonstrated in cannabinoid-tolerant rats. The present study was designed to further explore this previous evidence by analyzing simultaneously in several motor areas of delta 9-tetrahydrocannabinol- (delta 9-THC)-tolerant rats: 1. Cannabinoid receptor binding, by using [3H]WIN-55,212-2 autoradiography; 2. Cannabinoid receptor activation of signal transduction mechanisms, by using WIN-55,212-2-stimulated [35S]-guanylyl-5'-O-(gamma-thio)-triphosphate ([35S]-GTP gamma S) autoradiography; 3. Cannabinoid receptor mRNA expression, quantitated by in situ hybridization. Results were as follows. As expected, the exposure to delta 9-THC for 5 d resulted in a decrease of cannabinoid receptor binding in the molecular layer of the cerebellum, medial, and lateral caudate-putamen and, in particular, entopeduncular nucleus. We also found decreased cannabinoid receptor binding in the superficial and deep layers of the cerebral cortex, two regions used as a reference to test the specificity of changes observed in motor areas. There were only two brain regions, the globus pallidus and the substantia nigra, where the specific binding for cannabinoid receptors was unaltered after 5 d of a daily delta 9-THC administration. However, in the substantia nigra, the magnitude of WIN-55,212-2-stimulated [35S]-GTP gamma S binding was lesser in delta 9-THC-tolerant rats than controls, thus suggesting a possible specific change at the level of receptor coupling to GTP-binding proteins. This was not seen neither in the globus pallidus nor in the lateral caudate-putamen, where agonist stimulation produced similar [35S]-GTP gamma S binding levels in delta 9-THC-tolerant rats and controls. Finally, animals chronically exposed to delta 9-THC also exhibited a decrease in the levels of cannabinoid receptor mRNA in the medial and lateral caudate-putamen, but there were no changes in the cerebellum (granular layer) and cerebral cortex. In summary, the chronic exposure to delta 9-THC resulted in a decrease in cannabinoid receptor binding and mRNA levels in the caudate-putamen, where cell bodies of cannabinoid receptor-containing neurons in the basal ganglia are located. However, this decrease particularly affected the receptor binding levels in those neurons projecting to the entopeduncular nucleus, but not in those projecting to the globus pallidus and substantia nigra, although, in this last region, a specific decrease in the efficiency of receptor activation of signal transduction mechanisms was seen in delta 9-THC-tolerant rats. The chronic exposure to delta 9-THC also resulted in decreased cannabinoid receptor binding in the cerebellum, although without affecting mRNA expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10096037     DOI: 10.1385/JMN:11:2:109

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  32 in total

1.  Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry.

Authors:  P Mailleux; J J Vanderhaeghen
Journal:  Neuroscience       Date:  1992       Impact factor: 3.590

2.  Chronic exposure to delta 9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors.

Authors:  T M Westlake; A C Howlett; S F Ali; M G Paule; A C Scallet; W Slikker
Journal:  Brain Res       Date:  1991-03-22       Impact factor: 3.252

Review 3.  Search for endogenous ligands of the cannabinoid receptor.

Authors:  R Mechoulam; L Hanus; B R Martin
Journal:  Biochem Pharmacol       Date:  1994-10-18       Impact factor: 5.858

4.  Involvement of GABA(B) receptors in the motor inhibition produced by agonists of brain cannabinoid receptors.

Authors:  J. Romero; E. García-Palomero; J.J. Fernández-Ruiz; J.A. Ramos
Journal:  Behav Pharmacol       Date:  1996-05       Impact factor: 2.293

Review 5.  Cannabinoid pharmacology.

Authors:  W L Dewey
Journal:  Pharmacol Rev       Date:  1986-06       Impact factor: 25.468

6.  Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.

Authors:  A Oviedo; J Glowa; M Herkenham
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

7.  Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.

Authors:  E Fride; R Mechoulam
Journal:  Eur J Pharmacol       Date:  1993-02-09       Impact factor: 4.432

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  delta 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats.

Authors:  A P Wickens; R G Pertwee
Journal:  Eur J Pharmacol       Date:  1993-11-30       Impact factor: 4.432

10.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.

Authors:  M Herkenham; A B Lynn; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  J Neurosci       Date:  1991-02       Impact factor: 6.167

View more
  8 in total

1.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

Review 2.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

3.  Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat.

Authors:  Alexa A Wakley; Jenny L Wiley; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2014-08-02       Impact factor: 4.492

4.  Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.

Authors:  Maria Scherma; Christian Dessì; Anna Lisa Muntoni; Salvatore Lecca; Valentina Satta; Antonio Luchicchi; Marco Pistis; Leigh V Panlilio; Liana Fattore; Steven R Goldberg; Walter Fratta; Paola Fadda
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

Review 5.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

6.  Blockade of cannabinoid receptors reduces inflammation, leukocyte accumulation and neovascularization in a model of sponge-induced inflammatory angiogenesis.

Authors:  Rodrigo Guabiraba; Remo C Russo; Amanda M Coelho; Mônica A N D Ferreira; Gabriel A O Lopes; Ariane K C Gomes; Silvia P Andrade; Luciola S Barcelos; Mauro M Teixeira
Journal:  Inflamm Res       Date:  2013-05-31       Impact factor: 4.575

7.  Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning.

Authors:  Patrick D Skosnik; Chad R Edwards; Brian F O'Donnell; Ashley Steffen; Joseph E Steinmetz; William P Hetrick
Journal:  Neuropsychopharmacology       Date:  2007-07-18       Impact factor: 7.853

Review 8.  Cerebellar endocannabinoids: retrograde signaling from purkinje cells.

Authors:  Païkan Marcaggi
Journal:  Cerebellum       Date:  2015-06       Impact factor: 3.847

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.